Immunogenicity and Protection of a Variant Nanoparticle Vaccine That Confers Broad Neutralization against SARS-CoV-2 Variants

Researchers demonstrated that a recombinant prefusion-stabilized spike protein vaccine based on Beta/B.1.351 produced a robust anamnestic response in baboons against SARS-CoV-2 variants, when given as a booster one year after immunization with NVX-CoV2373.